德展健康(000813) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was approximately ¥482.51 million, down 51.07% year-on-year[8]. - Net profit attributable to shareholders of the listed company was approximately ¥96.30 million, a decrease of 66.37% compared to the same period last year[8]. - The net profit after deducting non-recurring gains and losses was approximately ¥77.98 million, down 72.60% year-on-year[8]. - Basic earnings per share were ¥0.0434, a decrease of 66.09% compared to the same period last year[8]. - The weighted average return on net assets was 1.73%, down 3.89% year-on-year[8]. - Total operating revenue for the current period is ¥482,506,209.18, a decrease of 51.1% compared to ¥986,089,744.94 in the previous period[63]. - Net profit for the current period is ¥95,754,034.85, a decline of 66.6% from ¥286,390,150.79 in the previous period[66]. - Total operating revenue for the current period is ¥1,404,387,771.12, a decrease of 47% compared to ¥2,647,093,599.10 in the previous period[80]. - Net profit for the current period is ¥337,687,727.29, a decline of 54% from ¥730,112,461.91 in the previous period[82]. - The company reported a profit before tax of ¥406,099,027.57, compared to ¥850,767,599.39 in the previous period[82]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥5.89 billion, a decrease of 0.56% compared to the end of the previous year[8]. - Total assets amounted to ¥11,023,057,707.39, an increase from ¥10,362,774,134.64 in the previous period[62]. - Total liabilities were CNY 274,874,043.14, down from CNY 640,152,430.60 year-over-year[49]. - Current liabilities reached CNY 255,722,765.02, significantly lower than CNY 623,790,558.88 in the prior year[49]. - The company reported a total asset value of ¥5,921,638,285.93[143]. - The total current assets increased to ¥2,076,909,614.31, reflecting a rise of ¥400,000,000.00[145]. - The total liabilities were reported at ¥608,458,447.31 for the current liabilities section[151]. Cash Flow - The net cash flow from operating activities for the year-to-date was approximately ¥1.43 billion, an increase of 534.70% compared to the same period last year[8]. - The net cash flow from operating activities increased by 534.70% to ¥1,433,007,121.50 from ¥225,776,379.62, mainly due to the collection of receivables and reduced sales expenses[24]. - The net cash flow from operating activities was 1,433,007,121.50 yuan, a substantial increase from 225,776,379.62 yuan in the prior year[126]. - The company reported a cash and cash equivalents balance of 765,309,134.71 yuan at the end of the period, down from 2,146,175,777.44 yuan at the end of the previous period[126]. - Cash inflow from investment activities totaled $1,712,137,354.89, significantly up from $122,141,906.30, indicating a substantial increase in investment returns[130]. Investments and Strategic Initiatives - The company plans to strengthen cooperation with HanZhong Group and HanMa Investment in the hemp health industry[25]. - The company signed a strategic cooperation framework agreement with HanZhong Enterprise Management Group and HanMa Investment Group for equity acquisition and comprehensive strategic cooperation[27]. - The company plans to establish a joint venture, "DeYi Pharmaceutical Co., Ltd." in Kunming, Yunnan, with a registered capital of RMB 10 million[27]. - The company has invested a total of RMB 10 billion in various financial products, including structured deposits and wealth management products, to manage idle funds[27]. - The company has signed multiple agreements for structured deposits, including RMB 3 billion with Ningbo Bank and RMB 2 billion with Ping An Bank[27]. Research and Development - Research and development expenses increased by 40.48% to ¥90,050,914.59 from ¥64,101,881.59, reflecting increased investment in R&D projects[24]. - Research and development expenses for the current period amount to ¥90,050,914.59, an increase from ¥64,101,881.59 in the previous period[80]. Shareholder Equity - Net assets attributable to shareholders of the listed company increased by 6.30% to approximately ¥5.61 billion[8]. - Owner's equity increased to CNY 5,613,627,322.04 from CNY 5,281,485,855.33, reflecting a growth in retained earnings[53]. - Total equity attributable to shareholders reached ¥5,281,485,855.33, while total equity was also ¥5,281,485,855.33[143]. Other Financial Metrics - The company received government subsidies amounting to approximately ¥16.10 million during the reporting period[8]. - The company reported a significant increase in other payables, which reached CNY 1,294,477,549.07 compared to CNY 608,284,435.20 in the previous year[59]. - The company has confirmed a bad debt provision of RMB 2.58 million related to a financial product from Baoshang Bank, with a total of RMB 145.6 million guaranteed by the People's Bank of China[34].